Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Azidothymidine and the nervous system].

R R Riedel1, L Bader, L Gürtler

  • 1Univ.-Nerven-Klinik München.

Fortschritte Der Medizin
|May 10, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Severe underquantification of HIV-1 group O isolates by major commercial PCR-based assays.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2020
Same author

Conceptualising production, productivity and technology in pharmacy practice: a novel framework for policy, education and research.

Human resources for health·2018
Same author

Vasoconstrictor eicosanoids and impaired microvascular function in inactive and insulin-resistant primates.

International journal of obesity (2005)·2016
Same author

Evaluation of the 'Jumping to conclusions' bias in different subgroups of the at-risk mental state: from cognitive basic symptoms to UHR criteria.

Psychological medicine·2016
Same author

[Comparison of Two Symptom-Triggered Treatments for Alcohol Withdrawal: HAES vs. SAB-P].

Fortschritte der Neurologie-Psychiatrie·2016
Same author

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2015
Same journal

[More information--less pain. Procedure in pain following amputation of limbs. Brachial plexus injury and nerve root avulsion. Interview by Susanne Kammerer].

Fortschritte der Medizin·1999
Same journal

[Galenic alternatives to unstable tocopherol acetate. "Smeared" or cheated?--Vitamin E in facial ointments].

Fortschritte der Medizin·1999
Same journal

[Gene diagnosis in the hand of the physician].

Fortschritte der Medizin·1999
Same journal

[Is non-toxic cancer therapy through biotechnology a possibility?].

Fortschritte der Medizin·1999
Same journal

[Smoking withdrawal in practice and clinic].

Fortschritte der Medizin·1999
Same journal

[The future of pancreas diagnosis. An exclusive training service of the Gastro-Ligue for dermatologists].

Fortschritte der Medizin·1999
See all related articles

This review examines early clinical data from 1988 regarding the effects of the drug Zidovudine on patients with HIV-related neurological issues. While some patients experienced temporary improvements in their symptoms, others faced significant side effects affecting their nervous systems.

Area of Science:

  • Neurology and clinical pharmacology research involving Azidothymidine
  • Infectious disease outcomes within clinical medicine

Background:

No prior work had resolved the full spectrum of neurological impacts associated with early antiretroviral interventions. Clinical observations during the initial stages of the HIV epidemic remained fragmented across various medical reports. This uncertainty drove a need to consolidate findings regarding patient responses to early pharmacological treatments. Researchers sought to understand how these therapies influenced cognitive and motor functions in affected populations. Prior research has shown that HIV frequently manifests through diverse neurological complications in advanced disease stages. The lack of comprehensive data synthesis hindered clinicians from accurately predicting treatment outcomes for these specific patients. This gap motivated a retrospective look at the available literature from the late nineteen eighties. Establishing a baseline for these early therapeutic experiences provides context for modern neuro-immunology practices.

Purpose Of The Study:

The aim of this review is to evaluate the neurological impact of Zidovudine treatment in patients with HIV-related conditions. This study addresses the uncertainty surrounding how early antiretroviral interventions affected the nervous system. Researchers sought to synthesize existing clinical reports to determine the frequency of both therapeutic benefits and adverse events. The primary motivation was to clarify the clinical profile of patients experiencing neurological or neuropsychological symptoms. No prior work had resolved the prevalence of these specific outcomes across such a large patient cohort. By examining data from over five hundred cases, the authors intended to provide a clearer picture of treatment efficacy. The study addresses the gap in understanding the risks associated with pharmacological management of HIV-related neurological issues. This analysis serves to inform the medical community about the observed clinical responses during the late nineteen eighties.

Keywords:
antiretroviral therapyneurological deficitsAIDS-Related Complexclinical outcomes

Frequently Asked Questions

The researchers propose that Zidovudine treatment led to a temporary reduction in neurological deficits for 38.8% of patients. In contrast, 23.6% of the individuals studied experienced adverse effects within their peripheral or central nervous systems.

The study focuses on 3'-Azido-2,3'Dideoxythymidine, commonly referred to as AZT. This antiretroviral agent was evaluated for its impact on neuropsychological signs in individuals diagnosed with AIDS or AIDS-Related Complex.

The authors indicate that clinical data from 525 patients were necessary to establish these trends. This large sample size allowed for a quantitative assessment of both positive therapeutic responses and negative neurological side effects.

The review utilizes published literature from before December 1988. This data type provides a historical snapshot of early HIV treatment protocols and their associated neurological manifestations in clinical practice.

Related Experiment Videos

Main Methods:

The review approach involved a systematic survey of medical literature published prior to December 1988. Investigators gathered reports detailing the experiences of patients diagnosed with AIDS or AIDS-Related Complex. The team focused exclusively on individuals exhibiting documented neurological or neuropsychological symptoms. Researchers extracted quantitative data regarding treatment efficacy and safety profiles from these compiled records. This methodology prioritized the aggregation of clinical outcomes across a large cohort of five hundred twenty-five subjects. The analysis excluded non-neurological patient data to maintain a specific focus on nervous system responses. Investigators categorized the findings based on reported improvements versus observed adverse events. This structured synthesis allowed for a clear comparison of therapeutic benefits and risks within the specified patient population.

Main Results:

Key findings from the literature reveal that 38.8% of patients experienced a temporary improvement in their neurological deficits. This positive response was documented in 204 out of the 525 total cases analyzed. Conversely, the data indicate that 23.6% of patients suffered from peripheral or central neurological side effects. These adverse reactions were recorded in 124 individuals within the study group. The results demonstrate a notable disparity between the frequency of symptom relief and the occurrence of toxicity. These figures provide a quantitative baseline for understanding the impact of early antiretroviral therapy on the nervous system. The findings suggest that while some patients benefited, a significant portion faced neurological complications. This evidence highlights the dual nature of the treatment outcomes observed during that period.

Conclusions:

The synthesis suggests that Zidovudine therapy produced mixed outcomes for individuals suffering from HIV-related neurological deficits. Authors noted that over one-third of the reviewed cases experienced a transient reduction in their symptoms. These findings highlight the complexity of managing central nervous system involvement during viral infections. The data also indicate that nearly one-quarter of patients encountered adverse reactions affecting their peripheral or central nerves. These observations imply that the therapeutic window for such interventions requires careful monitoring by medical professionals. The authors emphasize that while some benefits exist, the risk of neurological toxicity remains a significant concern. This review underscores the necessity of balancing efficacy against potential harm in clinical settings. Future assessments should continue to weigh these early clinical experiences against contemporary standards of care.

The researchers measured the frequency of neurological improvement and side effects. They identified that 204 cases showed symptom relief, whereas 124 cases exhibited neurological complications, demonstrating the dual nature of the treatment.

The authors suggest that clinicians must remain vigilant regarding the potential for neurological toxicity. They imply that the observed side effects necessitate a cautious approach when administering this medication to patients with existing neurological signs.